Preliminary therapeutic and localization studies with human chorionic gonadotrophin

Area of Science:

• Oncology
• Immunotherapy
• Medical Imaging

Background:

• Tumor-secreted proteins are potential targets for cancer therapy and diagnosis.
• Heterologous antibodies have been explored for their potential in targeting these tumor markers.

Purpose of the Study:

• To evaluate the therapeutic efficacy of heterologous antibodies against tumor markers in patients and preclinical models.
• To assess the utility of radiolabeled antibodies for tumor localization.

Main Methods:

• Preliminary therapeutic studies combined anti-HCG and anti-alpha-fetoprotein antibodies with chemotherapy in patients.
• In vivo studies involved administering anti-HCG to nude mice inoculated with choriocarcinoma cells.
• Radioiodinated (131I) anti-HCG and anti-carcinoembryonic antigen antibodies were used for tumor imaging in human and murine models.

Main Results:

• Therapeutic outcomes in patients with drug-resistant choriocarcinoma and malignant teratoma were interesting but inconclusive.
• Anti-HCG administration did not inhibit choriocarcinoma growth in nude mice.
• Tumor localization studies achieved specific:nonspecific ratios of up to 2:1 using radiolabeled antibodies.

Conclusions:

• Heterologous antibodies targeting tumor-secreted products like HCG and alpha-fetoprotein have shown limited success as standalone therapies.
• Antibody-based imaging demonstrates potential for tumor localization but requires further optimization for specificity.